Fortress Biotech Announces Exclusive Worldwide License Agreement With AstraZeneca and Cincinnati Children’s Hospital Medical Center to Develop a Novel Treatment for Select CNS Disorders

Baergic Bio, a Fortress partner company, enters into an agreement with AstraZeneca for AZD7325, a novel a2/3–subtype-selective GABA A positive allosteric modulator

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.

4 COMMENTS

Comments are closed.